FENDX TECHNOLOGIES INC - FDXTF STOCK NEWS

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) has successfully completed its pilot manufacturing phase for REPELWRAP™ film in collaboration with Dunmore International Inc. The company is now advancing to real-world assessment of the film's repelling effectiveness at various test venues. This marks a important step towards finalizing the product for commercial production.

Dr. Carolyn Myers, CEO of FendX, expressed excitement about this milestone, emphasizing the importance of real-world testing in providing valuable insights into the film's performance. The company acknowledges the significant contributions of Dunmore International Corp. and McMaster University in reaching this stage of development.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has announced the publication of research results demonstrating its AI-enhanced nanotechnology's ability to detect bacterial contamination on surfaces with 96.7% accuracy. The study, conducted at McMaster University, was peer-reviewed and published in 'Advanced Functional Materials' on July 30, 2024.

The technology, derived from FendX's licensed nanotechnology, incorporates a color-changing surface coating that transitions from blue to green-yellow to indicate bacterial biofilm formation. Using AI machine learning, it achieves 100% sensitivity and 95% accuracy in contamination detection.

Carolyn Myers, President and CEO of FendX, highlighted the potential of this technology for infection prevention and control in healthcare settings. The company also announced the resignation of Andrea Mulder as COO, effective August 30, 2024.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has appointed Dr. Rohit Ramchandani as an advisor to leverage his extensive public health expertise in advancing innovative solutions for pathogen control and safety. Dr. Ramchandani, a global expert in public health and infectious disease control, brings nearly two decades of experience in designing, implementing, and scaling innovative approaches for disease control and health system strengthening.

His role at FendX will be to inform, advise, and support the company's mission to develop surface protection coatings that reduce pathogen spread. Dr. Ramchandani's expertise, particularly in pandemic response and antibiotic resistance, aligns with FendX's goal of addressing growing public health threats. His appointment is expected to contribute significantly to FendX's efforts in creating groundbreaking solutions for mitigating pathogen transmission and improving overall well-being.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) highlights a new CDC report showing a 20% increase in infections from six antibiotic-resistant bacteria ('superbugs') in 2021 and 2022 compared to 2019. The CDC attributes this rise partly to COVID-19's impact on healthcare systems, longer hospital stays, and antibiotic overuse.

The report emphasizes the need for more effective infection prevention and control strategies. FendX, a nanotechnology company developing surface protection coatings, aims to contribute to reducing superbug spread. Dr. Carolyn Myers, CEO of FendX, states that the company is dedicated to developing innovative high-touch surface protection solutions to combat superbug transmission and enhance safety.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has successfully completed a pilot scale-up run of its REPELWRAP™ film with Dunmore International Corp. The company reports that the produced film met performance expectations using a streamlined manufacturing process. Dr. Carolyn Myers, CEO of FendX, expressed satisfaction with the progress and stated that this advancement brings them closer to real-world testing with various industry partners in long-term care, fitness, and entertainment sectors.

FendX plans to conduct another pilot manufacturing run with Dunmore in the coming weeks, which they believe will be the final run before advancing to real-world testing. The company acknowledges the valuable collaboration with Dunmore and McMaster University in reaching this stage. Additionally, FendX granted 55,000 restricted share units (RSUs) to a consultant, vesting in three equal installments over the next three months.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D), a nanotechnology company developing surface protection coatings, has announced the grant of stock options and restricted share units (RSUs) to certain directors, officers, employees, and consultants. The company granted 3,950,000 stock options at an exercise price of $0.29, expiring in five years, with a vesting schedule of 50% on the grant date and 25% each at nine and eighteen months. Additionally, 1,150,000 RSUs were granted to two officers and a consultant, following the same vesting schedule. These grants are in accordance with the company's equity incentive plan dated October 19, 2021, and are subject to a four-month and one-day hold period from the grant date.

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) has announced plans to conduct real-world testing of its REPELWRAP™ film with LA Fitness at their Vaughan location near Toronto, Ontario. This marks the sixth testing site for FendX's nanotechnology surface protection coating. The company is collaborating with Dunmore International Inc. for pilot manufacturing runs of REPELWRAP™ film.

The testing at LA Fitness will involve applying the film to high-touch surfaces over approximately four weeks to assess its repelling capabilities, as previously demonstrated in McMaster University's lab. This partnership with LA Fitness, a well-established gym chain with 690+ locations across North America, aims to provide valuable insights into the film's performance in a high-traffic environment.

FendX Technologies Inc. (CSE: FNDX, OTCQB: FDXTF) responded to a request from OTC Markets Group Inc. regarding recent promotional activities related to its common shares. On June 18, 2024, OTC Markets highlighted promotional content distributed by Spartan Trading Inc., an affiliate of Spark Newswire Inc., which FendX had engaged for investor relations and digital marketing services since May 9, 2024. FendX reviewed and commented on this content, which included factual statements about the company. FendX stated it is unaware of any unusual trading activity resulting from this promotion. Furthermore, FendX confirmed that neither its management nor the consultants have engaged in significant trading of the company’s securities in the past 90 days, except for Spartan, which transacted 55,000 shares. FendX reiterated that it is an early-stage issuer with growth objectives yet to be realized and advised investors to review its continuous disclosure filings for comprehensive risk disclosures.

FendX Technologies, a nanotechnology company specializing in surface protection coatings, has released a corporate update highlighting key milestones and future plans. CEO Dr. Carolyn Myers reported significant advancements in the development and commercialization of the company's REPELWRAP™ film. The automation of the manufacturing process is being optimized through pilot runs, with commercial production expected to begin by the end of 2024. Testing sites for the film include various high-traffic locations such as restaurants and care facilities. The company also announced progress in its medical catheter nano-coating project, which aims to reduce bacterial biofilms and blood clots, and a new spray nanotechnology formulation that's more scalable. Additionally, FendX raised over $2.86M through private placements and warrant exercises. The company continues to build its intellectual property portfolio and seeks further growth through partnerships and acquisitions. Future goals include completing the scale-up of REPELWRAP™, finalizing the spray formulation, and starting proof-of-concept studies for the catheter project.